網頁

醫藥 - 美中醫學交流學會 11/18 哈佛中醫藥論壇12/3 CABA 12/9 首屆世界針灸康養大會12/2-7

ACMES Annual Conference 2017

2017-11-11 ACMES ACMESBoston


ACMES Annual
Conference 2017

Join us for ACMES Annual Conference 2017! The American Chinese Medical Exchange Society will host a FREE annual conference on Saturday, November 18, 2017. 


November 18th, 2017
@Amenise Building 125
210 Longwood Ave., Boston, MA
(On the right wing of Harvard Medical School main building )
  • Primary care centered management for Common Chronic Diseases  
  • Transnational Research Advances
  • Better Clinical Care Model
  • Common Chronic Disease Managements
  • Case Discussion
  • Legal and Insurance Aspects
  • Medical Career Path
Admission

RSVP is required, seating limited, no registration fee.
Click 阅读原文/Read more in the bottom of page for reservation.
Morning Session

8:00am Registration 
8:45am Opening remarks 
9-9:40 “Immunotherapy and Endocrinology” by Le Min, MD, PhD, Brigham and Woman’s Hospital, Assistant Professor of Harvard Medical School. 
9:40-10:10 “Advances in Cardiovascular disease 2017” by Peter Kang, MD, BIDMC, Associate Professor of Harvard Medical School. 
10:10-10:50 “Non-glycemic effects of new medications for diabetes: does this change anything” by Margo Hudson, MD, Brigham & Woman’s Hospital, Assistant Profession, HMS 
10:50-11:00 Coffee break 
11:00-12:00 “Advance in Hepatitis C and case study” (CLDF) by Keqin Hu, MD. Professor of University of California at Irvine 
12-1:00pm Lunch provided
Afternoon Sessions
1-1:30 “Medical Treatment of Obesity” by Dr. Zhao Liu, MD, Lahey Clinic 
1:30-2:00 “Biological Circadian and Sleep Health” Yanwei Chen, MD, Shenzhen Hospital 
2:00-2:30 “Legal Perspective of Medical Practice: Case studies” by David Gould, Esq. 
2:30-3:00 “Medical Insurance, coverage and medical billing” Rose Rum, Harvard Pilgrim 
3:00-3:10 Coffee break 
3:10-3:40 “Incorporate Pharmacogenomics into Clinical Practice”. Zeil Rosenberg, MD, Vice President, Medical Affairs at Admera Health. 
3:40-4:10 “General Medicine, a new specialty in China” Qiaoxin Yang, MD, North Shore Medical Center 
4:10-4:30 “Traditional Chinese Medicine, why? 20 years of experience in US” John Zhang, PhD, L.Ac, President of Massachusetts Society of Chinese Medicine, Professor of Beijing University of Chinese Medicine. 
4:30-5:00 Postdoc and Student presentation session 
“Immunotherapy: CD8+ T cells-Burn fat and gain fit” by Dr.Ying Zhang (Boston Children Hospital) 
“ End Organ Damage is a risk factor of refractory ITP“ by Dr. Tianle Zou (Brigham & Woman’s Hospital) 
“Current treatments for Prader-Willi Syndrome: A Systematic Review” by Mr.Junli Zhu (Fisher College). 
5:00-5:30 break

Evening Sessions
5:30-6:30 Dinner presentation 
    “Advance in Hepatitis B and case study” Calvin Pan, MD, Director of Hepatology, Professor of NYU 
6:30-7:00 Q & A for Dr. Pan 
7:00-8:00  "ACMES, achievement and future perspective" by Xuejun Kong, MD 
"Award presentations" by Drs.Keqin Hu and Weigen Li 
8:00-9:30 ACMES annual celebration: Singing, Dancing, Guzheng, Guita, Taiji, and more by invited professional musicians, dancers and Taiji master…
美中医学交流学会 2017年年会在哈佛医学院盛大召开

美中医学交流学会今年最重头的年会将于1118日(周六))在哈佛医学院盛大召开!
届时中、美医学医疗大师、教授、专家学者将激情讲演初级保健为中心的常见慢性病管理,转化研究进展,更好的临床护理模式,案例讨论,医学法律、医疗保险、医生职业等主题。
优秀博士后们也将展示他们最有新意的研究成果。

肝病专家在晚宴演讲中将会把乙肝诊断、治疗中的各色各样案例一一加以独到分析、高度概括总结。

晚宴中最后高质量的中外歌曲演唱,独舞、群舞表演,中外器乐演奏等一定让你陶醉其中。
整个活动免费(我们有幸获得慷慨赞助),但要预先注册。

注册处:http://acmes.net/
时间:201711188:30am9pm
地点:@Armenise Building 125210 Longwood Ave., Boston, MA哈佛医学院主楼前面大草坪的左侧楼
联系:info@acmes.net

电话:孔学君781-325-6804, 牛江河857-234-6696

 P哈佛中醫藥
Harvard Chinese Medicine Forum

Time:  3:30-8:30pm Sunday December 03, 2017
Place:
  Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478 FRANCIS de MARNEFFE
Parking: Free
CEUs (Continue Education Credit): 4 creditsFee $60 including dinner ($25 value) 
    Free for Dr. Lee’s group, Harvard Faculty/Fellow without dinner, $25 with dinner.

Sponsored: Massachusetts Society of Chinese Medicine (MSCM)
           Alternative Medicine Center, McLean Hospital, HMS
Program

3:30-4:00pm Registration (Registration will close at 4pm, please come by 4pm)
4:00-5:00pm Acupuncture for Pain – Free discussion, experience sharing and questioning 
 
5:00pm-7:00pm 痛症的治疗思路和针刺要点
  Acupuncture Treatment Strategies for Pain & Key Points of Needling
 
7:00-8:30pm Dinner & Discussion
 
Speaker:  美国著名的中医针灸专家刘伟博士, Dr. Wei Liu, PhD, L. Ac
Contact     
             Call Dr. Li 617 323 7809 or 
             email:Johnzhang999@gmail.com
 

刘伟教授,医学博士,毕业于中国天津中医药大学针灸骨伤专业。现为明州执业中医师,主持东方针灸推拿医疗中心,是全美知名的中医针灸师和针灸学教授。1999 年开始在西健康科学大学(NWHSU)协助开办针灸系并担任教授至20171月。2004起担任泼特兰市俄勒冈大学东方医学(OCOM)首届博士班客座教授并连任至今,多次在太平洋中医大会,大河中医大会,及哈佛医学院举行中医讲座。2016 月受聘成为中美针灸康复研究所的第一批特聘教授和专家委员会成员,成立了刘伟针灸工作室。20174月,受聘为广州中医药大学客座教授。20175月,入选海外华侨华人中医药 “百人百项”工程,成为10名首批入围的海外中医药专家之一。刘伟教授勤勉治学,功底深厚,推崇与精通古典针法,独创了刘氏头针,腹针,风筝,张力牵引针等多套针法,形成了自己独特的系统与风格,享有“针法大师”的美誉,在北美地区独立办班讲学,讲课风格深入浅出,生动风趣,好评如潮,在海外中医界享有盛名。

The 20th SAPA-NE Scientific Symposium
Genetic and Rare Diseases -
New Technologies and Emerging Therapeutics
Dear Members and Friends:
We are very pleased to announce the 20th SAPA-NE Scientific Symposium will be held in MIT on Nov 11th, 2017.
The theme of the symposium is“Genetic and Rare Diseases-New Technologies and Emerging Therapeutics". The symposium will bring together leading scientists, clinicians, and executives to present and discuss scientific breakthroughs, innovative technologies, and creative approaches in drug discovery and development for genetic and rare diseases.
The symposium will also offer plenty of opportunities for networking and connecting with colleagues in academic and biopharma communities.
We look forward to seeing you at MIT!
With kind regards,
Organization Committee

The 20th SAPA-NE Scientific Symposium

Genetic and Rare Diseases-New Technologies and Emerging Therapeutics

Date: 1:00 pm - 6:00 pm, Saturday, November 11th, 2017
Location: Building E25-111, MIT Deacon/Carleton St, Cambridge, Massachusetts

Registration:
Free for all active SAPA-NE members and MIT students
$15 for students and postdoctoral fellows
$30 for all other participants
Thank you for your donation to SAPA-NE. Please fill in all the information.
This donation is not refundable.Thank you.


CABA header
NEWSLETTER
November 11, 2017
2017 CABA Medical Device & Diagnostic Innovation Symposium
Presented by Chinese-American BioMedical Association (CABA)

Co-organizer: NECINA and HMS-CSSA

When: Saturday, December 9th, 2017 (10:00 AM – 6:00 PM)

Where: Harvard Medical School, Folkman Auditorium of Boston Children's Hospital, 320 Longwood Ave. Boston, MA 02115
Admission
CABA members: FREE; Non-members: $30.
On-site membership registration available ($30 annual membership fee due).

Parking
Free garage parking validated by Organizer
Garage address: 333 Loongwood Ave., Boston, MA 02115
Entrance: 91 Binney Street

Conference Organizing Committee Contact
Jeff Hang, PhD,
WeChat: hangjf2014

The annual CABA Medical Device and Diagnostic Innovation Symposium is an influential event attracting prominent entrepreneurs, biotech and pharma executives, academic and industry scientists, as well as professionals from the healthcare fields. The theme of this symposium is “Innovation, Commercialization and Collaboration”. Topics of this year’s symposium will include new frontiers in medical device and diagnostics, entrepreneur experience, venture capital investment, partnership & collaboration, etc. The symposium provides a great opportunity to network with hundreds of professionals including scientists, entrepreneurs, investors, et al in the United States and China.

Agenda

9:30am - 10:00am Registration
10:00am - 10:15am Opening remark
10:15am - 12:30am Invited talks
12:30pm - 1:30pm Lunch
1:30pm - 5:00pm Invited talks
5:00pm - 5:10 Closing remark
5:10pm - 6:00pm Network

A detailed agenda will be available shortly.
Speakers

Bin Liu, Director of Division IV, Center for Medical Device Evaluation, CFDA
Yue Min, Reviewer, Division IV, Center for Medical Device Evaluation, CFDA
Regina Au, Principal of BioMarketing Insight
Mike Drues, PhD, President of Vascular Sciences
Grace Fu, MBA, CEO of China Med Device, LLC
Ellen Jiang, EMBA, Founder and President of RAMED
William Lee, PhD, VP of R&D and RA, AST Products
Yi Qian, PhD, VP of Product Management, MRSI Systems
Stavros Stefanis, PhD, Principal of Deloitte Consulting LLP
Rong Xia, MBA, MPH, CEO of Raiing Medical
About CABA

As a non-profit organization based in “Genetown”, CABA strives to facilitate the communication of the latest advances in biomedical R&D and commercialization, to assist in the exploration of new biotechnology and pharmaceutical market opportunities in the US and in China, and to promote career development and community services for its members. Since its inception, CABA has evolved into one of the most active and influential Chinese American professional organizations in the New England area. It has established a number of platforms, including seminars and workshops on R&D, commercialization, intellectual property, technology transfer and regulatory compliance, as well as many cultural and networking events.

2017中国针灸年会、世界针灸学术大会、首届世界针灸康养大会
各省、自治区、直辖市、计划单列市针灸学会,总会所属各分会、专业委员会、工作委员会、联盟及相关单位:
兹定于2017年12月2-7日召开“2017中国针灸年会、世界针灸学术大会、首届世界针灸康养大会”,主会场设在北京,分会场设在浙江省衢州市衢江区,大会诚挚的邀请国内外针灸专家学者、企业以及广大会员参加。现将相关事宜通知如下:
一、会议主题      针灸•世界•健康
二、日程安排
(一)北京主会场
12月1日,培训班报到;2日青年人才和临床研究培训班。
12月2日,2017中国针灸学会年会报到;3日上午开幕式和主题报告;3日下午分会场学术交流;4日上午专题论坛,下午离会。
(二)衢江分会场
12月5日,2017首届世界针灸康养大会报到;6日上午开幕式和主题报告,下午分会场学术活动;7日上午杨继洲祭拜活动和分会场活动,下午离会。
三、会议地点
(一)主会场地址
北京龙城丽宫国际酒店,北京市昌平区昌平路317号,对面华北电力大学。
(二)分会场地址
衢江东方大酒店,浙江省衢州市衢江区府前路7号。
四、大会语言
英语、汉语(中国普通话)。请所有发言专家准备中文、英文双语PPT,发言时间20分钟。
五、注册缴费
(一)北京主会场
1.会议费(含注册费及晚宴费)在10月31日前注册的按照如下四档享受优惠价格,上传有效会员证,学生证者,还可享受会员或学生优惠价格。
(1)国内普通参会代表注册标准:1500元/人
(2)国内会员参会代表注册标准:1300元/人
(3)国内学生参会代表注册标准:1200元/人
(4)国内学生会员参会代表注册标准:1000元/人
(5)11月1—30日注册标准:1800元/人
(6)现场注册缴费2000元/人
2.展位费:分会员单位和非会员单位(含2张晚宴餐券)
(1)普通参展单位展位费:12000元/位,面积:2m×3m
(2)会员参展单位展位费:10000元/位,面积:2m×3m
(二)衢江分会场
1.注册费:800元/人
2.展位费(含2人注册费):5000元/位,面积:2m×3m
说明:在北京主会场已注册缴费的代表,如继续报名参加衢江分会场活动,可免衢江分会场的注册费,交通费、食宿费自理。
六、会议注册缴费方式
(一)个人或团体公对公付款
请使用线下银行对公转账或网银对公转账支付,请汇到如下中国针灸学会指定账户,并请注明“2017中国针灸学会年会会议费或展位费”、“首届世界针灸康养大会会议费或展位费”。
账户/收款人:中国针灸学会
账号:0200004309089106718
开户行:中国工商银行北新桥支行
学会财务部联系人:王淑芬,联系电话:18701322139。
(二)网络注册缴费平台
使用会议平台在线扫描二维码码支付,请与付款单位财务做好沟通,避免发票报销时产生不必要的问题。个人账户在线支付支持网银、支付宝、微信支付。
扫描二维码后,通过填写参会人员信息,可将报名、交费、提交论文等一站式完成。学会信息部联系人:易文军,联系电话:13911789502 。
中国针灸学会年会网络注册平台二维码:
(三)现场缴费
现场可接受报到缴费。由于参会人数较多,会务组建议尽可能采取上两种方式提前缴费注册,以便于提前协助参会代表预订宾馆住宿。所有参会代表的食宿由会议统一安排,住宿费、交通费回本单位报销。

(一)中国针灸学会
联系人:文碧玲、李荫龙、易文军(展览展示)
电话:(010)64089964,64089962
传真:(010)64030959
地址:北京市东城区东直门内南小街16号
邮政编码:100700
电子邮箱:caamxsb@163.com
(二)中国中医科学院针灸研究所
联系人:李亮
电话:(010)64060868
传真:(010)64032682
地址:北京市东城区东直门内南小街16号
邮政编码:100700
电子邮箱:liliang1160@139.com
(三)浙江省衢州市衢江区
联系人:汪泽群、毛莉晨
手机:13600509730,18868196575
传真:+86-570-3838120
邮箱:409136468@qq.com,463756011@qq.com 邮编:324022ogram



Time: 2:00 PM - 4:30 PM, Oct. 12th, Thursday
Location: Room 11081, 11th Floor, CLS Building3 Blackfan Circle, Boston, MA, 02115
Free Registration: Press the QR code below or click "Read more" at the end of this post.






Join us for the day-long discussion with U.S. and Chinese healthcare leaders!

The 7th U.S.-China Health Summit is coming on September 15, at Harvard Medical School! Join us to hear senior managers like the Chief Health Officer of IBM Watson Health, renowned scholars from Harvard and Peking Union Medical College, as well as hospital executives and policy makers discuss important healthcare challenges and opportunities.
This is a great opportunity for those interested in the global healthcare industry. If you want to catch up with latest healthcare trends in U.S. and China, learn more about a career in healthcare, and expand your network with dedicated leaders in healthcare, or if you are just looking for opportunities to broaden your horizons regarding global issues, we sincerely invite you to the 7th U.S.-China Health Summit!

Themed “Megatrends in Health and Healthcare,” the 7th U.S.-China Health Summit will discuss:

1) the changing world and emerging health challenges;
2) megatrends in health and medical sciences and technology; 
3) megatrends in healthcare service innovation.


Confirmed speakers and their speech topics include: 
Ezra Vogel
Henry Ford II Professor of the Social Sciences Emeritus, Harvard University
“From Deng Xiaoping to Xi Jinping: the New Era of China”
Donald Ingber
Founding Director, Harvard Wyss Institute
“Breakthrough Discoveries Cannot Change the World If They Do Not Leave the Lab”
David Blumenthal
President, Commonwealth Fund
“ObamaCare, TrumpCare, and the Future of US Healthcare” 
Yuanli Liu
Dean, Peking Union Medical College School of Public Health
“Public Health Achievements and NCD Challenges in China”
Shaoping Deng
President, 
Center of Translational Medicine, the Chinese Academy of Sciences
“China’s Comparative Advantage and Weakness in Medical Research and Translation” 
Steve Chen
Founder and CEO, 
Third-Brain Research Institute

“Supercomputers Grid for Healthcare Cloud and Brain/Cancer Research, Genetics Engineering, Precision Medicine and Cancer Immunology Therapy”
Jingwei Liu
Director of Healthcare Innovation, China Electronic Sciences Inc.
“Developing a People-Centered Active Care Model in China”
Robert Huckman
Professor of Business Administration, Harvard Business School
Making Healthcare a Consumer Product"
Jing Ma
Associate Professor,
Brigham & Women’s Hospital

Why Chinese Doctors are Unhappy? A Report From China
Arthur Kleinman
Professor of Medical Anthropology in Social Medicine, Harvard Medical School
"Mental Health in China in the Context of Global Health"
Randall Moore
President, Mercy Virtual Health
“Virtual Health"
Kyu Rhee
Vice President and Chief Health Officer, IBM Watson Health
"Future of Health is Cognitive"
Peter Juhn
Vice President and Global Head of Value-Based Partnerships, Amgen
“Value-Based Contracting"
Brent James
CTO, Intermountain Healthcare
"Strategies to Lower Costs, Improve Quality, and Engage Patients"
Bill Sibold
CEO, Sanofi Genzyme
(Speech Topic TBD)
Jack Spengler
Akira Yamaguchi Professor, Harvard T.H. Chan School of Public Health
"Cities, Climate Change & Health: A Future Not Informed by the Past"
(Speakers and topics may be subject to slight change as needed.)
More speakers are detailed on our website.

Tickets
Tickets for different groups (industry, general public and students) are now available on our Eventbrite on a first come, first served basis.
Industry tickets include VIP dinner – a unique chance to talk with Summit speakers & guests and learn more about future opportunities in Chinese healthcare market! 
If you have any questions, feel free to email us at info@uschinahealthsummit.org
and we will reach out to you shortly. We look forward to witnessing with you how U.S. and Chinese healthcare leaders are moving forward together!
Register for the 7th U.S.-China Health Summit right now!
Stay updated with the Summit on our social media:
Facebook
Facebook
Twitter
Twitter
LinkedIn
LinkedIn
About U.S.-China Health Summit

U.S.-China Health Summit (the Summit) has been dedicated to advancing global health by promoting exchange of knowledge, ideas and experiences among the current and future health sector leaders from China, the U.S. and other countries.
The annual Summit has become an important part of the U.S.-China Strategic and Economic Dialogue, as well as the People-To-People Exchange Program. Last year, over 200 scholars, 300 company representatives, 400 government officials and 1,100 hospital executives from both the U.S. and China attended the 6th Summit, discussing a variety of academic, policy and investment topics in 10 forums.


 2017年对全球医疗卫生事业是意义非凡的一年。中国于今年启动了“健康中国2030长期规划”,政府与民间正如火如荼地投入到医疗大健康的领域;美国的政府与民间也在医疗健康领域积极寻求变革策略。本届峰会以“大健康,大趋势”为主题,将重点探讨:

      1)全球卫生健康面临的复杂挑战
      2)健康和医学科学技术的大趋势
      3)健康和医疗服务创新大趋势

我们诚挚邀请您参与这场中美医疗界的年度盛会,共同探讨未来的健康医疗大趋势!峰会现开放注册,注册请扫描文末二维码。

部分演讲嘉宾:
Ezra Vogel
哈佛大学社会科学荣誉教授
主旨演讲
William Haseltine
ACCESS健康国际有限公司董事长兼总裁
Arthur Kleinman
哈佛医学院社会医学人类学教授
刘远立
北京协和医学院公共卫生学院院长
Mark Elliott  
哈佛大学国际事务副教务长
Kyu Rhee
IBM Watson Health副总裁兼首席卫生官
Randall Moore
Mercy Virtual Health主席
 David Blumenthal
英联邦基金会主席
Robert Huckman
哈佛商学院工商管理教授
Donald Ingber
哈佛威士研究所创始主任
Alan Trager
公私伙伴关系倡议创始人兼主任; 清华大学PPP研究中心国际比较研究中心首席专家
孙喜琢 
深圳市罗湖医院集团总院长
更多重量级嘉宾及详情请关注中美健康峰会官方网站:uschinahealthsummit.org
或点击下方“阅读原文
峰会注册请扫下方二维码:
Time:
Sep 9th (Saturday) 2017, 10am - 2pm
Location:
Dana Building 1620, Dana-Farbar Cancer Institute
450 Brookline Ave, Boston, MA 02215
Lunch will be provided

纳斯达克上市公司
中国最大的细胞治疗公司——
西比曼生物科技公司
(Cellular BioMedicine Group)
西比曼全球分布
加州 | 马里兰 | 上海 | 无锡 | 北京


Tony Liu, CEO
曾担任阿里巴巴全球副总裁
微软中国首席财务官和全球战略总经理


Yihong Yao, CSO
曾担任Medimmune/阿斯利康制药公司药物基因组学和生物信息学高级总监
雅培制药公司高级科学家
西比曼目前临床试验产品

• 美国加州政府干细胞专项支持机构(CIRM)资助开展的异体人源脂肪干细胞治疗膝骨关节炎(临床试验I/II期)
• 嵌合抗原受体T细胞疗法(CAR-T)治疗急性B淋巴细胞性白血病,非霍奇金淋巴瘤, 多发性骨髓瘤以及各种实体瘤(临床试验I/II期)

主办单位

美中生物医药协会 
哈佛大学医学院华人专家学者联合会

The 7th U.S.-China Health Summit (the Summit) is coming in September. As the organizing committee, we invite you to attend the first part of the Summit, which will be held on September 15, 2017 in Boston.
Since its inauguration in 2011, the Summit has been dedicated to promoting exchange of knowledge, ideas and experiences of healthcare leaders from the U.S., China, and other countries. Last year, over 200 scholars, 300 company representatives, 400 government officials and 1,100 hospital executives from both the U.S. and China attended the 6th Summit, discussing a variety of academy, policy and investment topics in 10 forums.
This year, we are still boosting that communication and collaboration. 2017 is a unique year, marking both the inception of China’s implementation of the Healthy China 2030 Plan and the beginning of President Trump’s new Administration. Since the annual Summit has been held alternately in the U.S. and China since 2011, and by tradition this year’s Summit shall be held in the U.S., this year we will have a Boston Part (Part 1) of the Summit on September 15. In addition, we will organize a Beijing Part (Part 2) of the Summit on September 23, following the Centennial Celebration of Peking Union Medical College (PUMC)
Themed “Megatrends in Health and Healthcare,” this year’s Summit will focus on: 1) the changing world and emerging health challenges; 2) megatrends in health and medical sciences and technology; and 3) megatrends in healthcare service innovation.
Confirmed keynote speakers of the Boston Part include:
  • Mark Elliott, Vice Provost for International Affair, Harvard University
  • Arthur Kleinman, Professor of Medical Anthropology in the Department of Social Medicine, Harvard Medical School
  • Yuanli Liu, Dean, PUMC School of Public Health
  • William Haseltine, Chairman and President, ACCESS Health International, Inc.
  • Ezra Vogel, Henry Ford II Professor of the Social Sciences Emeritus, Harvard University
  • Kyu Rhee, Vice President and Chief Health Officer, IBM Watson Health
  • Randall Moore, President, Mercy Virtual Health
  • David Blumenthal, President, Commonwealth Fund
  • Xuetao Cao, President, PUMC
  • Robert Huckman, Albert J. Weatherhead III Professor of Business Administration, Harvard Business School
  • Donald Ingber, Funding Director, Harvard Wyss Institute
  • Alan TragerFounder and Director, Public-Private Partnerships Initiative; Chief Specialist, International Comparative Research, Tsinghua University Center for PPP Research (TUPPP)
The list may be subject to slight change. Tickets are sold on a first come, first served basis, and we are offering early bird discounts for registration before August 21.
For more information about this year’s or past Summit, please refer to our website: www.uschinahealthsummit.org, or email us at: info@uschinahealthsummit.org. We look forward to witnessing with you how healthcare leaders from the U.S., China, and other countries are moving forward together!






WuXi NextCODE Completes $240 Million Series B Financing
Investment from leading technology and healthcare investors will accelerate the growth of the global platform for genomic data

The global platform aims to empower institutions and individuals to realize the full value of their genomic data - to benefit human health and contribute to advancing precision medicine
SHANGHAI and CAMBRIDGE, Mass. and REYKJAVIK, Iceland, Sept. 7, 2017 /PRNewswire/ -- WuXi NextCODE, the global platform for genomic data, today announced the successful completion of a $240 million Series B financing.
The company extended and completed the Series B round with investment from a consortium led by Sequoia China and including TemasekYunfeng Capital and 3W Partners. Temasek, Yunfeng and 3W also participated in the initial Series B round in May alongside Amgen Ventures and other existing long-term investors and partners.  China Renaissance Group is the sole financial advisor to WuXi NextCODE in the latest financing round.
"The success of this financing round, which includes some of the top technology and healthcare investors worldwide, underscores the breadth and depth of confidence in our vision: to serve as the global platform for using genome data to advance global health," said Hannes Smarason, CEO of WuXi NextCODE. "We have the unique expertise and now the resources to execute on this strategy. We plan to continue to push the leading edge of technology for digitizing, managing and analyzing genomic big data, including through our pathbreaking AI, and to put it at the service of ever more enterprises, institutions, and individuals around the world."
"Genomics is an intrinsically global big data opportunity of unprecedented scale, and with breakthroughs in artificial intelligence, there will be explosive growth opportunities in the field of precision medicine," said Neil Shen, founding and managing partner of Sequoia China. "Sequoia China attaches great importance to investment in genomics and precision medicine. In leading WuXi NextCODE's latest financing round, Sequoia China is able to support the company to build out a standard platform to efficiently turn sequence data into benefits for people worldwide. This is truly where healthcare and technology meet."
"Our mission is to enable anyone to use the genome so that everyone can benefit from it," said Dr. Ge Li, chairman of WuXi NextCODE and founder and chairman of WuXi AppTec. "That is why we are building the global platform for genomic data and why we so pleased to have attracted such a stellar group of investors who not only share our vision but are uniquely positioned to support our growth. Only a platform with millions of genomes can provide the network effect and knowledge base that enable everyone to derive greater benefit, continually attracting more users, more data, and delivering ever more powerful health insights to serve people and patients everywhere."

WuXi NextCODE is using the proceeds from this round to accelerate the extension of its platform infrastructure and to bring new users and data onboard through precision medicine and diagnostics partnerships; the commercialization of its consumer solutions for the China market; and ultimately by enabling individuals to take charge of their own genomic data and deploy it to advance health and healthcare.


AUGUST AT-A-GLANCE
  • YHIF2017 Boston competition is rounded off
  • The 7th U.S.-China Health Summit is coming on September 15

YHIF2017 Achieved a Great Success!

Young Health Innovators Forum (YHIF) held its 2017 Boston competition on August 5. From among 62 applicants, we selected 12 as U.S. semi-finalists to pitch their ideas. Each team presented innovative solutions to unmet needs in today’s fast-growing healthcare market, impressing our judges and the audience with how latest technologies can advance healthcare. Nonspec, MobioSense, Z Imaging and XenoTherapeutics became U.S. finalists and are invited to the final round of YHIF2017 in Beijing.
Click here to learn more about YHIF2017 teams and their innovative ideas! 

“Our minds are challenged yet inspired. We learned so much from the amazing young people this afternoon! I’d like to quote Dr. Gross, a Nobel Laureate: ‘The more we know, the more we are aware of what we know not.’”
--Olivia Ho Cheng, Board member of the U.S.-China Health Summit

DESCRIPTION

Boston Taiwanese Biotechnology Symposium is held by Boston Taiwanese Biotechnology Association (BTBA), a non-profit organization established by Taiwanese professionals in biology-related fields in 2012 in Boston. We strive to bridge the academics and industry gap in the U.S. and Taiwan and to meet the needs of professionals in biology-related fields.
This year, we are honored to introduce Dr. Lily Y. Jan (Professor of UCSF; member of National Academy of Sciences and Academia Sinica) and Dr. James C. Liao (President of Academia Sinica; member of National Academy of Sciences and Academia Sinica) as our keynote speakers.
Highlights of our program include:
  • Panelists from both academia and industry to discuss the latest research, potential applications, and clinical development of “CRISPR technology” and “Immunotherapy”.
  • A new session on “Advancing your career” to learn about leadership and people skills, and how to exercise those skills and plan strategically to develop and establish a successful career in academia and industry.
  • A new session on “Commercialization of life innovation” to learn about technology transfer, the role of venture capital, and more about entrepreneurship.
  • Academic panelists from the U.S. to share their experience in research and career path in Academia.
  • Explore and build your career path in biotech or pharma by connecting with people from diverse fields.
  • Meet researchers from Academia Sinica. You may submit your CV to be considered in 1-on-1 setting.
  • Roundtable lunch with panelists
The annual meeting aims to provide platforms for interactions among young professionals, postdocs and students to share experiences and learn insight in diverse bio-related career paths.
The Summit invite you to attend the upcoming Young Health Innovators Forum 2017 (YHIF2017) Boston competition, which will be held at Harvard T.H. Chan School of Public Health on August 5 from 12:00 pm to 5:00 pm.

As an important part of the Summit, YHIF aims at helping young health innovators address unmet healthcare needs with innovative technologies and business models. This year, 12 teams will present their projects, which cover digital health, pharmacy, biotech, and other healthcare-related subjects. We will invite four finalists to Beijing to present their ideas in front of hundreds of hospital executives, pharmaceutical gurus, and investors.

We believe this is a great chance for you to catch up with latest healthcare investment hotspots, as well as meet many young healthcare professionals. You can find more details about the event on our website and get the free tickets of YHIF2017 by registering here. We look forward to seeing you this Saturday!
About U.S.-China Health Summit
The U.S.-China Health Summit is dedicated to the advancement of global health by promoting the exchange of knowledge, ideas, and experiences of healthcare leaders from the U.S., China, and other countries through high-level strategic dialogues, leadership development programs, and applied research. Click here to learn more about us.
The 7th U.S.-China Health Summit (the Summit) is coming in September. As the organizing committee, we invite you to attend the first part of the Summit, which will be held on September 15, 2017 in Boston.
Since its inauguration in 2011, the Summit has been dedicated to promoting exchange of knowledge, ideas and experiences of healthcare leaders from the U.S., China, and other countries. Last year, over 200 scholars, 300 company representatives, 400 government officials and 1,100 hospital executives from both the U.S. and China attended the 6th Summit, discussing a variety of academy, policy and investment topics in 10 forums.
This year, we are still boosting that communication and collaboration. 2017 is a unique year, marking both the inception of China’s implementation of the Healthy China 2030 Plan and the beginning of President Trump’s new Administration. Since the annual Summit has been held alternately in the U.S. and China since 2011, and by tradition this year’s Summit shall be held in the U.S., this year we will have a Boston Part (Part 1) of the Summit on September 15. In addition, we will organize a Beijing Part (Part 2) of the Summit on September 23, following the Centennial Celebration of Peking Union Medical College (PUMC)
Themed “Megatrends in Health and Healthcare,” this year’s Summit will focus on: 1) the changing world and emerging health challenges; 2) megatrends in health and medical sciences and technology; and 3) megatrends in healthcare service innovation. Confirmed keynote speakers of the Boston Part include:
Mark Elliott, Vice Provost for International Affair, Harvard University
Arthur Kleinman, Professor of Medical Anthropology in the Department of Social Medicine, Harvard Medical School
Ezra Vogel, Henry Ford II Professor of the Social Sciences Emeritus, Harvard University
Robert Huckman, Albert J. Weatherhead III Professor of Business Administration, Harvard Business School
The list may be subject to slight change. Tickets are sold on a first come, first served basis, and we are offering early bird discounts for registration before August 21.
For more information about this year’s or past Summit, please refer to our website: www.uschinahealthsummit.org, or email us at: info@uschinahealthsummit.org. We look forward to witnessing with you how healthcare leaders from the U.S., China, and other countries are moving forward together

7/27: US-CHINA Healthcare Transaction Lessons

2017-07-14 Xiaoyang 斐药圈
Topic:
US-CHINA Healthcare Transaction Lessons 

Date:
July 27th, Thursday from 7:00pm to 9:00pm

On Thursday, July 27th, San Francisco Healthcare Drinks, CABS, and ChinaMed Capital will host a talk by Carey Chern, General Counsel of SciClone entitled 'Lessons Learned from US-CHINA Cross Border Healthcare Transactions'. Chinese life sciences companies and Investors (e.g., PE and venture capital firms) are interested in doing transactions with US companies, including M&A, licensing and other commercial transactions.  Carey will provide his legal perspective on US companies entering into transactions with Chinese entities.

About Carey

Carey Chern joined SciClone in October 2016 and serves as General Counsel and Corporate Secretary, as well as SciClone's Chief Compliance Officer. Prior to joining SciClone, from 2011 to 2016, Mr. Chern served in various roles at The Clorox Company covering healthcare matters. Prior to The Clorox Company, Mr. Chern served in various roles at Amgen Inc. Prior to Amgen, Mr. Chern served as an attorney in several large international law firms covering life sciences and corporate transactions matters. Mr. Chern earned a J.D. from Stanford Law School and his A.B. in Economics and Government from Harvard University.

Event Location:
1633 Old Bayshore Hwy, Suite 280, Burlingame, CA 94010.
Contact Us:
Brian Hakim: +1(415)-902-6510     
Clare Gu:+86-186-163-16925     

RSVP:
To RSVP, please send your full name and company name to 
Sanfrancisco@healthcaredrinks.com


斐药圈(ChinaMed Capital Group)
Symposium program can be found on our website: http://btbatw.org/2017

19th SAPA-NE AC Brochure

点击注册
Greetings from Conference Chair
Dear SAPA Members and Friends:
On behalf of the organizing committee, it is my great pleasure to welcome you to the 19th Annual Conference of the Sino-American Pharmaceutical Professionals Association New England (SAPA-NE). SAPA-NE is a non-profit organization founded in 1998 and currently serves more than 2000 pharmaceutical/biotech professionals. Our mission is to serve its members and foster their career development through conference/symposium/networking and to promote exchanges and collaboration across pharmaceutical/biotech industries and academics between China and the US.
Our annual conference is SAPA-NE’s most prestigious event. Every year we bring together leaders from academia and industry, investors and entrepreneurs from around the world to share the cutting-edge discovery, exciting clinical development, and experiences and trends in business and career in life sciences. The theme of this year’s conference is "Convergence: Transformation of Life Sciences in Boston".
Boston is now recognized as the epicenter of innovation for both biologics and small molecules R&D in the world. More than 400 large and small biopharmaceutical companies have established headquarters or research centers here, plus many world-leading hospitals and prestigious universities, among them are Novartis, Pfizer, Sanofi, Biogen, Merck, Astra-Zeneca, AbbVie, Bristol-Myers Squibb, Takeda, Shire, EMD Serono, J&J and Bayer etc., as well as numerous small innovative companies. It’s difficult to fathom that this healthy and thriving ecosystem has not always been here. It started almost 10 years ago deep in the financial crisis that affected global economy. The Life Science Initiative enlisted the input and resources from government agencies, industry leaders, academic institutions, venture capitalists, and law firms. What we have witnessed since is an unprecedented growth in translating research discovery into therapeutic development. The game-changing immunotherapy in cancer treatment, the potential applications of genome editing technology such as CRISPR-Cas9, are just a couple of many areas that local companies are working on. This is the golden area of life sciences innovation, and Boston is the place where it all happens.
There are multi-national pharmaceutical companies overcoming cultural and organizational challenges to locate research centers in Boston area. There are local startups successfully raising capital when the overall trend is less than ideal. There are talented scientists helping accelerate the R&D process by crossing over between academia and industry. Those are the reason behind the theme for this year’s annual conference, to celebrate what makes Boston uniquely attractive to life sciences – the convergence of all the essential elements needed for transformation. This full day event will include plenary sessions, panel discussion, and a dinner reception. Biopharma industry senior executives, Chinese returnee entrepreneurs, and other experts will share their visions on scientific innovation, high-tech entrepreneurship, new trends in R&D globalization and strategies. Local and Chinese companies will bring a variety of job opportunities and set booths to recruit talents.
This year’s annual conference dinner reception is generously supported by our Diamond Partner, Greenberg Traurig, LLC, which is celebrating its 50th Anniversary. A keynote speech titled “Convergence of Law and Biopharma” will be given by Dr. Fang Xie, co-lead of its Biotechnology and Pharmaceutical Group.
Finally, I would like to express my most sincere gratitude towards all the members of the conference organizing committee for their outstanding work and unparalleled dedication in making this event possible. I am also grateful for all our valued sponsors for their generous and continued support. Everybody is welcome to join SAPA-NE and together we build an even stronger community. Thank you!
Sincerely yours,
Larry Cai, MBA, MS.
SAPA-NE 19th Annual Conference Chair
SAPA-NE President Elect 2016-2017
Conference Program
8:00 – 9:00
Registration and Breakfast
Opening Remarks
9:00 – 9:10
Mr. Larry Cai, Conference Chair, SAPA-NE President-Elect
Hon. Deval Patrick, Governor, Massachusetts (2007-2015)
Mr. Jijun Xing, Counselor of S&T, Consulate General of P. R. China
Session 1: Cutting Edge of Biomedical Innovation in Boston
Chairs: Drs. Jun Johnny Yang, Xingfeng Bao, Kejie Li, Lin Lin, Jing Tong
9:10 – 9:45
Dr. Andy Plump, Chief Medical and Scientific Officer, Takeda
“The Future of Drug Discovery: Innovation-driven Research & Development at Takeda”
9:45 – 10:20
Dr. Richard Murray, CEO and President, Jounce Therapeutics
“Immunology meets oncology: breakthroughs in immunotherapy”
10:20 – 10:50
Coffee Break and Exhibition
10:50 – 11:25
Dr. Sven Ante “Bill” Lundberg, CSO, CRISPR Therapeutics
“Bringing CRISPR Therapeutics to the Clinic”
11:25 – 11:50
Dr. Luhan Yang, CSO, eGenesis
“Gene Editing to Transform Xenotransplantation”
11:50 – 12:10
Dr. James Yang, President/CEO of Abpro China
“Fast Road Map for Biologic R&D”
12:10 – 1:00
Lunch and Exhibition
Session 2: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Mangeng Cheng, Dapeng Chen, Haishan Li, and Bing Ma
1:00 – 1:20
Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery”
1:20 – 1:40
Dr. Shidong Jia, Founder & CEO, Predicine Holdings Ltd.
“Precision medicine: clinical application of liquid biopsies in cancer”
1:40 – 2:00
Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
“Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs”
2:00 – 2:20
Ms. Jane Li, Co-founder, AF Recruiting
“Landscape of Healthcare Job Market in China”
Panel Forum: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Tianxiao Sun and QiYing Hu
2:20 – 3:20
Dr. Shaohui Huang, Zhongshan Tsuihang New District
Dr. Ruhong Jiang, Applied Stemcell
Dr. Jinbo Lee, Scilligence
Dr. John MacDougall, CrownBio
Dr. Weimin Tang, Hengrui Therapeutics Inc.
Dr. Tony Xie, Xiyu Investment Company
3:20 – 3:50
Coffee Break and Exhibition
Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences
Chairs: Mr. Larry Cai, Drs. Guiqing Liang and Jianzhu Chen
3:50 – 4:20
Dr. Lijun Wu, Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
“From Seed to Exit in 15 Months: The Delinia Story”
4:20 – 4:50
Dr. Yinxiang Wang, Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Zhejiang Betta Pharmaceuticals
“Challenges and Strategies of Innovative Drug R&D in China”
4:50 – 5:25
Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
“Follow the Science and Capture the Opportunities”
5:25 – 5:30
Closing Remark: Dr. Jiang Long, President of SAPA-NE
SAPA-NE 19th Annual Conference Dinner Reception (Ticket Required)
Sponsored by Greenberg & Traurig, LLP
(Location: Samberg Conference Center, 50 Memorial Drive, Cambridge MA)
Chair: Dr. Jiang Long, President of SAPA-NE
6:00 – 6:30

6:30 – 6:35


6:35 – 6:45



6:45 – 7:00



7:00 – 7:10


7:10 – 9:00
GT HomeNetworking

Welcome Remarks
Dr. Jiang Long, President of SAPA-NE

Keynote Speech
Dr. Fang Xie, Co-lead, Global Life Science, Greenburg Traurig, LLP
“Convergence of Law and Biopharma”

SAPA-NE Cooperate Service Award/Service Award Presentations
Dr. Jiang Long and Mr. Larry Cai/ Drs. Bingli Ma, Mark Lin, Xiaotian Zhong, Min Chen

SAPA-NE High School Excellence Scholarship Presentation
Drs. Huo Li and Guiqing Liang

Dinner/Networking

Opening Remark

Honorable Deval Patrick
Governor, Commonwealth of Massachusetts (2007-2015)

Deval 2.jpg






Jijun Xing, Ph.D.
Science and Technology Counselor, Chinese Consulate-General in New York

邢继俊(简历照)








Session 1: Cutting Edge of Biomedical Innovation in Boston

http://www.takeda.us/images/usr/default/header_logo_ci.jpg
Andy Plump, MD, PhD Chief Medical and Scientific Officer, Takeda Pharmaceuticals
Presentation title: The Future of Drug Discovery: Innovation-driven Research & Development at Takeda





Richard Murray, Ph.D., Chief Executive Officer and President
Presentation title: Immunology meets oncology: breakthroughs in immunotherapy




Logo
Dr. Sven Ante “Bill” Lundberg, Chief Scientific Officer, CRISPR Therapeutics
Presentation title: Bringing CRISPR Therapeutics to the Clinic



http://www.egenesisbio.com/uploads/2/8/6/4/28647375/1472768483.png
LUHAN YANG, Ph.D., Co-Founder and CSO
Presentation title: “Gene Editing to Transform Xenotransplantation




James Yang, Ph.D., President and CEO, Abpro-China
Presentation title: “Fast Road Map for Biologic R&D





Session 2: Collaborations and Opportunities Across the Ocean
http://www.wuxiapptec.com/images/logo1.png
Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Presentation title: Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery
http://www.predicine.org/uploads/4/6/3/9/46396713/logo-vision.png
Shidong Jia, Ph.D., Founder & CEO, Predicine Holdings Ltd
Displaying image1.JPGPresentation title: “Precision medicine: clinical application of liquid biopsies in cancer”




Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
Presentation Title: Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs






Ms. Jane Li,
Co-founder of AF Recruiting
Presentation title: Landscape of Healthcare Job Market in China




Panel Forum: Collaborative Innovation and Partnership




Shaohui Huang, Ph.D., Business Consultant, Zhongshan Tsuihang New District; President & Co-Founder, LightEdge Technologies, Ltd.; Professor, Institute of Biophysics, Chinese Academy of Sciences







Applied StemCell
Ruhong Jiang, Ph.D.,
Co-founder, President and CEO, Applied StemCell, Inc.





Jinbo Lee, Ph.D., Co-founder and Chief Scientific Officer of Scilligence Corporation





John MacDougall, Ph.D., Director of Scientific Engagement, CrownBio




Image result for jiangsu hengrui medicine
Weimin Tang, Ph.D., Head of BD, Jiangsu Hengrui Medicine Co.





logo.png
王利春,科伦药物研究院常务副院长,国家大容量注射剂工程技术研究中心主任






Mr. Shuijiang Zhou, Founder, Xiyu Investment Company




Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences

https://atlasventure.com/wp-content/uploads/Delinia.png
Lijun Wu, Ph.D., Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
Presentation title: “From Seed to Exit in 15 Months: The Delinia Story”



Beijing Jacobio Pharmaceuticals Co.,Ltd
Yinxiang Wang, Ph.D., Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Betta Pharmaceuticals
Presentation title: Challenges and Strategies of Innovative Drug R&D in China




Logo
Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
 Presentation title: Follow the Science and Capture the Opportunities


Dinner Reception Keynote Speech
Dinner Keynote Speaker:
Fang Xie, Ph.D.
Of Counsel, Co-lead, Global Life Sciences, Greenberg Traurig, LLP, Boston

Presentation title: The Convergence of Law and Biopharma”





Diamond Partner

https://pbs.twimg.com/profile_images/819255504463478784/7PLlkNxG.jpg

Platinum Partner

http://www.wuxiapptec.com/images/logo1.png


Media Partner

Gold Partner


http://www.predicine.org/uploads/4/6/3/9/46396713/logo-vision.png
Silver Partner

Applied StemCell https://www.bms.com/content/dam/bms/us/en-us/downloads/BMS-logo.jpg
Image result for jiangsu hengrui medicine logo.png http://www.takeda.us/images/usr/default/header_logo_ci.jpg
https://vcanbioctbblog.files.wordpress.com/2017/02/cropped-20160816015810429.jpg?w=300


Event Partner
http://www.aberjonalabs.com/images/header.jpg Achemtek
Logo Image result


Beijing Jacobio Pharmaceuticals Co.,Ltd
China CRO Company,Preclinical research services
Selleck Chemicals Logo https://www.wyzerbio.com/wiser/image/top-banner.jpg

Directions to Tang Center
Address: Tang Centrer, 70 Memorial Drive, Cambridge, MA 02142
Due to construction activities in the area, many parking lots are no longer available. It is highly recommended to carpool or to take public transportation to the event. The closest subway station (T) is Kendall Square stop (Red-line).
Parking (important notice!)
There is a small parking lot (E51 lot) for Tang Center with limited number of spaces shown in the map below. Also, there are several public parking lots or garages in Kendall Square area in walking distance to Tang Center.
One closest parking garage (3 blocks walking distance to Tang Center) is shown below:
Kendall Square South Garage ($11 on Saturday), 350 Kendall St, Cambridge, MA 02142
点击注册

19th SAPA-NE Annual Conference

         June 17, 2017@MIT

        广  欢  阵  药

        积  迎  容  协

        人  参  强  年

        脉  加  大  会

Registration link:

http://www.sapa-neweb.org/AC2017.php


Registration to 19th SAPA-NE Annual Conference 2017

19th SAPA-NE Annual Conference 2017


Date: 9:00 am - 6:00 pm (Conference), Saturday, Jun 17th, 2017
Dinner Event: 6:30 pm - 9:30 pm, Saturday, Jun 17th, 2017
Location: MIT Sloan School of Management, Tang Center, Wong Auditorium, Cambridge, MA

Registration:
Free for all active SAPA-NE members and MIT students
$15 for students and postdoctoral fellows
$30 for all other participants
Thank you for your donation to SAPA-NE. Please fill in all the information.
This donation is not refundable.Thank you.


Confirmed Speakers:

Andrew “Andy” Plump, M.D., Ph.D., Chief Medical and Scientific Officer, Takeda 



Yong-Jun Liu, Ph.D., Head of Research, Global R&D, Sanofi



Richard Murray, Ph.D., Chief Executive Officer and President, Jounce Therapeutics 



Sven Ante “Bill” Lundberg, Ph.D., Chief Scientific Officer, CRISPR Therapeutics 



Yinxiang Wang, Ph.D., Chief Executive Officer, Jacobio Pharmaceuticals, Co-found of Betta Pharma 



Lijun Wu, Ph.D., Entrepreneur-in-Residence, Atlas Ventures, SVP at Delinia (now Celgene) 



Luhan Yang, Ph.D., Co-founder and Chief Scientific Officer, eGenesis 



James (Jianguo) Yang, Ph.D., President & CEO, Abpro-China Shidong Jia, Ph.D., Founder & CEO, Predicine Holdings Ltd

哈佛医学院中医药论坛
Traditional Chinese Medicine Forum-HMS

Time: 9:00am-6:00pm Sunday August 6, 2017

Place: Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont,

MA 02478 FRANCIS de MARNEFFE (cafeteria)

Parking: Free 
CEUs (Continue Education Credit): 9 credits

Fee (lunch included): 

Need 9 CEU Credits: $130 for MSCM members; $180 for non-members

Free for Dr. Lee’s group, Harvard Faculty/Fellow (Please contact us, reservation needed)

Sponsored: Massachusetts Society of Chinese Medicine (MSCM)

Alternative Medicine Center, McLean Hospital, HMS
Program

9:00-9:15am Registration

9:15-12:30pm “针灸治疗花粉过敏症临床观察及特效针法演示”
Acupuncture for the treatment of seasonal allergies 
& Special techniques Demo

12:30-2:00pm Lunch & discussion

2:00pm-6:00pm “常用针刺手法实际操作技巧临床应用研究”
Clinical use of acupuncture techniques and Demo

Speaker: 纽约著名的中医专家林榕生博士, Dr. Rongsheng Lin

Contact 
Call Dr. Li 617 323 7809 or 
Email:Johnzhang999@gmail.com
一 简介: 林榕生: 纽约著名中医专家,中医针灸博士,主任医师,现为世界中医药学会联合会副主席、国际中医药专业高级技术职称评审委员会委员、世中联骨伤科、外治方法研究及穴位埋线等专业委员会副会长;世界针灸学会联合会执委、世针联中医针灸传承工作委员会副主任委员、美国中医药学会董事局主席,福建中医药大学美国校友会会长,美国大纽约中医针灸学会总顾问、全美华裔中医组织联合会副主席,国际中医药联盟美容养生专家委员会副主任委员,福建中医药大学等多所大学以及中国全军针灸培训中心客座教授,联合国教科文组织人类非物质文化遗产代表作名录中医针灸代表性传承人张缙教授亲传入室弟子。

二,上午讨论的题目:“针灸治疗花粉过敏症临床观察及特效针法演示”

三,下午讨论的题目:“常用针刺手法实常用针刺手法实际操作技巧临床应用研究”


CABA美中生物医药协会2017年会暨十周年庆典召开在即

 2017-04-11 Jo Lee CABA
“Boston BioForum 2017”
CABA10th Annual Conference
Coming Soon!!!
🏨Boston Marriott Newton
📍2345 Commonwealth Ave, Newton, MA 02466
🕙10:00 AM to 6:00 PM on Saturday, May 6, 2017.

SPEAKERS

Gordon Freeman

Professor at Harvard University

Carmen Bozic, MD
Carmen Bozic MD is Senior Vice President of Global Development at Biogen, accountable for developing, obtaining and maintaining regulatory approval of therapies in Biogen’s therapeutic focus areas of Neurodegenerative and Rare Diseases. Dr. Bozic is an experienced drug development leader with 18 years of progressively increasing responsibilities in the biopharmaceutical industry.
Kenneth I Kaitin, Ph.D.
Dr. Kaitin is Professor of Medicine and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kaitin alsoholds appointments as Advisory Professor at Shanghai Medical College of Fudan University in China; Visiting Executive at the Tuck School of Business at Dartmouth College; and faculty of the European Center for Pharmaceutical Medicine at the University of Basel.
Ken LeClair, Ph.D.
Ken LeClair received his undergraduate degree from BowdoinCollege and a Ph.D. in Immunobiology from Yale University.
He did a postdoc at the MIT Center for Cancer Research andhad an academic appointment as Assistant Professor of Medicine in theImmunology Division of the Beth Israel Deaconess Medical Center at the Harvard Medical School.
He joined Editas Medicine late in 2016 and is working to help bring CRISPR-based therapies to the clinic and to market.
Samarth Kulkarni, Ph.D.
Samarth(Sam) Kulkarni is the Chief Business Officer of CRISPR Therapeutics since 2015.  At CRISPR, Sam is responsible for Corporate Strategy, Business Development, and Investor Relations. Sam has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. 
Xinyu Weng, Ph.D.
Weng, Xinyu, Ph.D, is First Secretary of the Embassy of the People’s Republic of China to the United States of America. As the primary point ofcontact for China Food and Drug Administration (CFDA) in the U.S., Dr. Weng is committed to strengthening bilateral food and drug regulatory cooperation between China and the U.S., and reaching out to the U.S. food and drug industry.
Lynn Yang, MBA
Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital in May,2015, Lynn worked at Legend Capitalhealthcare team. Lynn accomplished investment deals in different area of healthcare industry. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product managerat GE Healthcare.  
Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.
Jason Fisherman, MD, MBA
Jason is an investor in medical innovation, drug developer, and company founder. He has worked to build life science companies as a managing director at the global private equity firm Advent International and subsequently as co- founder of the venture spin-out Synthesis Capital. Jason has funded more than thirty companies that have brought over ten new products to market.
James (Jianguo) Yang, Ph.D.
Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China. Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in Abbott Lab Pharma Division, MedImmune /Astra Zeneca, and Genzyme / Sanofi.

Junzhi (John) Yao, Ph.D.
Dr. Junzhi (John) Yao received his PhD degree in chemistry from Wuhan University. He joined Medicure Inc. in Winnipeg, Canada as a Research Scientist conducting drug discovery research for cardiovascular diseases and stroke.

In 2009, Dr. Yao co-founded TC Scientific Inc. in Edmonton, Alberta, Canada, which has become one of the top CROs in Canada.
Hui Cai, Ph.D.
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances,and Head of PR and Corporate Communications.
Prior to WuXi, Dr. Cai spent 10 years at Johnson& Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmunediseases.


Agenda

09:00 - 10:00 am      Registration / Social and Networking
10:00 - 10:05 am      Opening Remarks, Conference Chair
10:05 - 10:15 am      Introduction of CABA, President, CABA
Featured Speaker
10:15 - 11:00 am       Kenneth I. Kaitin,Ph.D., “The Global Landscape for Pharmaceutical R&D: Current Trends -Future Opportunities”
Session I -Immunotherapy: for the Cure ofCancer
11:00 - 11:35 am       Samarth Kulkarni,Ph.D. “CRISPR-based Therapeutics:  Making it a Reality in Asian Markets”
11:35 - 12:10 pm       Ken LéClair, “Development of Cell and Gene-edited Products”
LUNCH AND VENDOR SHOW: 12:10 - 1:30 pm (LunchProvided on Site)
LUNCHOEN PRESENTATION
12:45 - 1:15 pm  TC Scientific Presentation, John Yao, "A CRO's View of the Pharma Landscape"
SESSION II – Innovation,Investment, and Entrepreneurship
1:30 - 2:05 pm          Hui Cai, Ph.D. Wuxi (TBD ,)
2:05 - 2:40 pm          James Yang, Ph.D. “StrategicPartnership for Success in Biologics
2:40 - 3:15 pm           Lynn Yang, MBA, Sequoia Capital “Sequoia China HealthcareInvestment Strategy”
3:15 - 3:50 pm           COFFEE BREAK AND VENDOR SHOW
SESSION III - CFDA Regulatory reform and Innovation for the benefit ofPatients           
3:50 - 4:25 pm           Jason Fisherman, M.D.(TBD)
4:25 - 5:00 pm           XinYu Weng, Ph.D; MBA. “Overview onCFDA Drug Regulatory Reform”    
5:00 - 5:35 pm           Carmen Bozic, M.D. SVP GlobalDevelop. “Innovations in Intrathecal Antisense Oligonucleotide Therapy forNeurological Diseases”
5:35 - 6:00 pm          Closing Remarks and Networking
Registration:
Link: http://caba-annualmeeting-2017.eventdove.com
也可点击文末“阅读原文”或长按以下图片提取二维码直达注册页面。
同写意论坛第59期活动

中国在研药品的FDA法规注册之路

时   间
2017年6月3-4日
地   点
苏州·独墅湖世尊酒店
主   办
同写意新药英才俱乐部
承   办
北京梓潭管理咨询有限公司
协  办
复旦大学药学院
Humphries Pharmaceutical Consulting, LLC
博瑞生物医药(苏州)股份有限公司
新药创始人俱乐部
支持单位
海思科药业
杭州和泽医药科技有限公司
支持媒体

HPC药闻药事、米内网、新浪医药、GBI、药事纵横、健点子ihealth、汤森路透、药智网、药物简讯、苏比亚、易贸医疗、药渡、医药信息新药开发群、医药研发社交平台、药物临床试验网、投壶网、火石创造、贝壳社、汇聚南药、当代医生、中睿医药评论、中国医药报、医药经济报、Insight数据库、新药汇、药物一致性评价、药研、药研汇、洛施德GMP咨询

HKS Science + Innovation Diplomacy Symposium
The HKS Science + Innovation Diplomacy Symposium aims to put a spotlight on the intersection of Science and innovation with diplomacy and how these two elements act as drivers for solutions to foreign policy challenges.
The Science + Innovation Diplomacy Symposium will provide a space for a trilateral exchange between Academia, Policy makers and the Private Sector to discuss “common ground” where science and innovation can be used as a bridge between governments and people.
Saturday, April 15, 2017 | 9:00AM - 3:30PM
Starr Auditorium, 5th Floor, Belfer Building
79 John F. Kennedy Street
Cambridge, MA, 02138
This event is free and open to the public. As space is limited for this event, RSVPs will be accepted on a first come, first served basis.
At the Harvard T.H. Chan School of Public Health on Friday, April 7th for the 2017 Health Equity & Leadership Conference themed “Advocacy and Leadership for Health Equity.”

Closing keynote: Dr. Elisa Choi, Chairperson of the Commonwealth of MA Asian American Commission

Tickets are FREE and open to all. PLEASE REGISTER in advance through Eventbrite to ensure entry, as space is limited. Lunch and refreshments are included!

REGISTER HERE: http://bit.ly/2n5Raly

HEAL was formed in 2012 by a group of students at the Harvard T.H. Chan School of Public Health dedicated to generating discourse and action to resolve issues related to health inequities in the Boston and Cambridge communities. This year we aim to expand our scope to discuss how we can address health equity in a new administration from grassroots organizing to lobbying policymakers. We seek to foster a conversation between community members, students, and faculty about the causes of inequities, the role of community organizations in serving vulnerable populations, and innovative solutions for a more equitable future.

Featured speakers and panelists include:
* Thaddeus Miles, Director of Community Services at MassHousing)
* Dr. Benjamin Cook, Director of the Health Equity Research Lab and the Center for Multicultural Mental Health Research
* Eva Stahl, Director at Community Catalyst Children's Health Project
* Ashley Slay, Boston Area Rape Crisis Center
* Irvienne Goldson, Deputy Director of ABCD Health Services
* Dr. Nancy Oriol and Jennifer Bennet, Executive Director of The Family Van
and more to be announced!

See below for a tentative conference agenda:
*subject to changes*

8:30am - 9:30am- Registration & Breakfast
9:30am -10:20am- Opening Remarks
10:30am -12:20pm- Panels
- Panel #1 - Advocating for Health Equity: Translating Research & Policy into Action
- Panel #2 - Community-Based Approaches to Health Equity
12:30-1:30PM- Lunch
1:30pm-2:20pm- Workshops Session #1
- Grassroots Organizing
- Advocating for Health Equity in a Clinical Setting
- Negotiation and Conflict Resolution
2:30pm-3:20pm- Workshop Session 2:
- Negotiation and Conflict Resolution
- Public Speaking
- Social Entrepreneurship and Innovation
- Grassroots Organizing
3:30pm-4:30pm Closing Keynote


哈佛医学院中医药论坛
Traditional Chinese Medicine Forum-HMS

Time: 9:00am-5:00pm Sunday May 21, 2017
Place: McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478 FRANCIS de MARNEFFE (cafeteria)
Parking: Free 

CEUs (Continue Education Credit): 9 credits
Fee (lunch included): 
Need 8 CEU Credits: $90 for MSCM members; $120 for non-members
No CEU, Free for Dr. Lee’s group, Harvard employee (reservation needed)
Sponsored: Massachusetts Society of Chinese Medicine (MSCM)
Alternative Medicine Center, McLean Hospital, HMS

Program

9:00-9:15am Registration
9:15-12:00pm Integration of Stretching motion and Tuina with Acupuncture
导引运动,推拿与针灸的整合应用
12:00-1:30pm Lunch & discussion
1:30pm-5:00pm Holistic approach in treating neuroendocrine disorders
神经内分泌系统功能紊乱的中医与自然疗法
Speaker: Dr. Jing Liu, PhD, L.Ac


Contact 
Call Dr. Li 617 323 7809 or 
Email:Johnzhang999@gmail.com




Allurion Repays Massachusetts Life Sciences Center
Natick company has commercialized a gastric balloon technology
to combat obesity

Natick, MA - The Massachusetts Life Sciences Center (MLSC) and Natick-based Allurion Technologies announced today that the company, which was awarded a $750,000 Accelerator loan from the MLSC in 2011, has repaid the loan with interest after a successful funding round from private investors. Allurion’s repayment to the MLSC totaled $1,115,824.

Allurion’s flagship product is the Elipse™ gastric balloon, a procedureless™ medical device for weight loss.  The Elipse device comprises a balloon made of thin polymer film that is delivered in a 15-minute outpatient visit without need for anesthesia or surgery.  It is filled with water and resides in the stomach for four months, enabling weight loss which averages between 10% and 15% of starting weight.  At the end of therapy, a patented opening mechanism is automatically activated, allowing the device to empty and pass naturally.

At the time of the MLSC loan Allurion had three employees and was still developing its technology.  The company now has more than 20 Massachusetts-based employees.  Its product, which has not yet been approved by the FDA, is currently available in select weight loss centers in France, Italy, Belgium, Greece, the U.K., Spain, Kuwait, Saudi Arabia and Qatar, with plans for a U.S. clinical trial commencing in 2017.

Allurion has also served as a host company for the MLSC's Internship Challenge Program, hosting seven interns to date for which it has or will receive salary reimbursement through the MLSC. 

Allurion’s Chairman and CEO Jonathan Wecker said “the Accelerator loan from the MLSC did exactly what we needed – it accelerated our development and allowed us to build a case for traditional private investment.  We are grateful to the MLSC for its early confidence in our potential and are proud to have returned the funds, with interest, to the Commonwealth.”

“Our Accelerator Loan Program seeks to derisk promising earlystage companies and make them more attractive to private investors,” said Massachusetts Life Sciences Center President & CEO Travis McCready.  “We were pleased to provide early financial and workforce support to Allurion, both through our Accelerator Program and our Internship Challenge Program, as they built their company and developed this promising technology.  We look forward to seeing the ongoing positive impact that their technology will have on patients around the world.”

“The biotech sector is thriving across the state, and Allurion is a terrific example of innovation and entrepreneurship here in MetroWest,” said Senator Karen E. Spilka (D-Ashland). “This is a MLSC success story of a targeted investment in the life sciences cluster creating jobs and advancing critical technology. I look forward to continuing the state’s partnership with Allurion and other innovative life sciences companies in our community.”


“It is great to see that the MetroWest continues to be a leader in the research and development of life sciences,” said Representative David Linsky (D-Natick). “I look forward to the future projects that will come out of Allurion.”

SAPA-NE Career Development Symposium Career in Biotech Start-up and Entrepreneurship 
– Translating Research into Business, Ideas/Technology into Pipelines/Products 
MIT Maclaurin Building 4-370 182 Memorial Drive (Rear), Cambridge, MA 02138 
Saturday 1-6 PM, March 18, 2017 

Welcome to attend the 19th SAPA-NE Career Development Symposium on Saturday, March 18th, 2017 at MIT Maclaurin Building. The biopharma industry entrepreneurs and the experts in legal and venture capital will share their experience and perspective in successfully founding, managing or investing in biotech start-up(s) and overall insight and visions on scientific innovation and biotech entrepreneurship. The meeting will also provide the attendees an excellent opportunity to network with biopharmaceutical professionals around Boston area and to access some new job openings posted onsite. The Plenary Session Speakers include: Yi Zhang, Ph.D., a HHMI Investigator and Professor of HMS and BCH, and a co-founder of Epizyme Joy Alamgir, Entrepreneur, Founder, EVP and CSO of Consilience Software, A Xerox Company Chong Xu, Ph.D., Associate, F-Prime Capital Partners, Boston Ruhong Jiang, Ph.D., a co-founder, president and CEO of Applied Stem Cell Fang Xie, Ph.D., Of Counsel, Greenberg Traurig, LLP, Boston Follow by a panel discussion with all speakers plus Wei Zhao, Ph.D., Associate, Wuxi Healthcare Venture Online registration: http://sapa-neweb.org/CDS2017.php This event is free for SAPA-NE members and MIT students; $30 for non-members; $15 for students. (coorganizer MIT-CHIEF) SAPA-NE Career Development Symposium Organizing Committee 

U.S. Department of Homeland Security to Keynote at Biosurveillance Integration,
part of Biodefense World Summit

The national strategy for biosurveillance calls for a coordinated approach for threats to public health and safety, bringing together federal, state and local governments; private sector, nongovernmental organizations and international partners to enhance existing biosurveillance capabilities and develop new ones that provide decision makers and responders with the essential information to manage these threats. This strategy recognizes that a well-integrated national biosurveillance enterprise can save lives by providing essential information for better decision making at all levels. The Sixth Annual Biosurveillance Integration conference will address implementation strategies for the national strategy for biosurveillance identified core functions.
Luther LindlerBiosurveillance to Protect the Homeland
Luther Lindler, Ph.D., Senior Scientist (ST), Biological Programs, Chemical and Biological Defense Division Science and Technology Directorate, U.S. Department of Homeland Security
One of the Department of Homeland Security's (DHS) responsibilities is to protect the U.S. from a biological attack. The Science and Technology Directorate, through the Chemical and Biological Defense Division (CBD), has developed a Real Time Threat Awareness biosurveillance program that integrates information data streams with new detection technologies. This presentation will discuss the interest areas and progress DHS CBD is making toward building a 21st century biosurveillance program.

Dr. Lindler joined the DHS Science and Technology Directorate in October 2003 as a Senior Science Advisor. Dr. Lindler currently serves the Senior Scientist for biological programs within the chemical and biological defense division where he provides expertise to both DOD as well as DHS about current infectious disease threats from a global perspective. He currently serves on the Joint Influenza Surveillance Working Group for DOD, is the DOD representative to the Interagency Influenza Diagnostics Working Group, as well as senior advisor to DOD Health Affairs on technical diagnostic issues that affect force health protection. He currently manages several projects related to infectious disease for the AFHSC. The most notable is to bring forward deployed rapid molecular diagnostics to DOD forward deployed forces. He also serves on the National Biodefense Analysis and Countermeasures Center review committee for DHS S&T and has participated in the national Material Threat Assessment and Biological Risk Assessment programs. His first position within DHS was as the Science Advisor for the NBACC. He helped plan the NBACC forensics and threat characterization programs as well as the first DHS laboratory building on the Fort Detrick National Biodefense Campus. Before joining DHS, Dr. Lindler was a leader in the US Army Biodefense program. He was a principle investigator at the Walter Reed Army Institute of Research leading a team of professionals studying the pathogenesis of the plague bacterium. He served on the Army’s plague vaccine steering committee and the emerging threats steering committee within the Biodefense program. The peak of his career with the Army culminated with his senior editorship of the well-acclaimed Biodefense book entitled, “Biological Weapons Defense; Infectious Diseases and Counterbioterrorism.” Dr. Lindler was a postdoctoral fellow in the laboratory of Dr. Susan Straley at the University of Kentucky in Lexington from 1987 until 1989. Dr. Lindler received his Ph.D. in Microbiology from the Medical College of Virginia in 1987, his Masters of Science in Microbiology from Clemson University in 1981 and his Bachelor’s of Science in Medical Technology from Lenoir Rhyne College in North Carolina in 1978.